A phase 2 study evaluated the efficacy and safety of adding pembrolizumab to trimodal therapy as a bladder-sparing approach for muscle-invasive bladder cancer (MIBC).

A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National ...

More than half of patients with recurrent/advanced disease were progression-free at 6 mont ...

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...

Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...

In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics and branded drugmaker ...

The company reported that its drug candidate, also known as zoci, achieved a 62.5% confirmed intracranial response rate at the 1.6 mg/kg dose level among 16 patients in an ongoing global Phase 1 trial ...

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...

Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy ...

These data were simultaneously published in The Lancet: “ Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised ...

Lower rates of severe bone pain incidence seen for the 72-hour group vs 24- and 48-hour groups. HealthDay News — For patients with breast cancer, administration of pegfilgrastim 72 hours ...

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.